Literature DB >> 18766325

Genetic variation in the NOS1AP gene is associated with the incidence of diabetes mellitus in users of calcium channel blockers.

M L Becker, L E Visser, C Newton-Cheh, J C M Witteman, A Hofman, A G Uitterlinden, B H Ch Stricker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18766325     DOI： 10.1007/s00125-008-1143-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

1.  A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization.

Authors:  Dan E Arking; Arne Pfeufer; Wendy Post; W H Linda Kao; Christopher Newton-Cheh; Morna Ikeda; Kristen West; Carl Kashuk; Mahmut Akyol; Siegfried Perz; Shapour Jalilzadeh; Thomas Illig; Christian Gieger; Chao-Yu Guo; Martin G Larson; H Erich Wichmann; Eduardo Marbán; Christopher J O'Donnell; Joel N Hirschhorn; Stefan Kääb; Peter M Spooner; Thomas Meitinger; Aravinda Chakravarti
Journal:  Nat Genet       Date:  2006-04-30       Impact factor: 38.330

Review 2.  Electrophysiology of the pancreatic beta-cell.

Authors:  F M Ashcroft; P Rorsman
Journal:  Prog Biophys Mol Biol       Date:  1989       Impact factor: 3.667

3.  Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance.

Authors:  R R Shankar; Y Wu; H Q Shen; J S Zhu; A D Baron
Journal:  Diabetes       Date:  2000-05       Impact factor: 9.461

4.  A neuronal isoform of nitric oxide synthase expressed in pancreatic beta-cells controls insulin secretion.

Authors:  A D Lajoix; H Reggio; T Chardès; S Péraldi-Roux; F Tribillac; M Roye; S Dietz; C Broca; M Manteghetti; G Ribes; C B Wollheim; R Gross
Journal:  Diabetes       Date:  2001-06       Impact factor: 9.461

Review 5.  Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis.

Authors:  R Schulz; T Rassaf; P B Massion; M Kelm; J-L Balligand
Journal:  Pharmacol Ther       Date:  2005-06-08       Impact factor: 12.310

6.  Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study.

Authors:  Albert-Jan L H J Aarnoudse; Christopher Newton-Cheh; Paul I W de Bakker; Sabine M J M Straus; Jan A Kors; Albert Hofman; André G Uitterlinden; Jacqueline C M Witteman; Bruno H C Stricker
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

7.  Changes in the dimeric state of neuronal nitric oxide synthase affect the kinetics of secretagogue-induced insulin response.

Authors:  Anne-Dominique Lajoix; Martine Pugnière; Françoise Roquet; Jean-Claude Mani; Samuel Dietz; Nathalie Linck; Fleur Faurie; Gérard Ribes; Pierre Petit; René Gross
Journal:  Diabetes       Date:  2004-06       Impact factor: 9.461

8.  The Rotterdam Study: objectives and design update.

Authors:  Albert Hofman; Monique M B Breteler; Cornelia M van Duijn; Gabriel P Krestin; Huibert A Pols; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Johannes R Vingerling; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2007-10-23       Impact factor: 8.082
  8 in total
  9 in total

Review 1.  Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.

Authors:  Gaia Chiara Mannino; Giorgio Sesti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

2.  Lack of interaction of beta-cell-function-associated variants with hypertension on change in fasting glucose and diabetes risk: the Framingham Offspring Study.

Authors:  Jose M de Miguel-Yanes; Bianca Porneala; Michael J Pencina; Caroline S Fox; Jose C Florez; David S Siscovick; Josée Dupuis; James B Meigs
Journal:  J Hypertens       Date:  2013-05       Impact factor: 4.844

3.  Association of genetic variants of NOS1AP with type 2 diabetes in a Chinese population.

Authors:  C Hu; C Wang; R Zhang; M C Ng; Y Bao; C Wang; W Y So; R C Ma; X Ma; J C Chan; K Xiang; W Jia
Journal:  Diabetologia       Date:  2009-11-24       Impact factor: 10.122

4.  NOS1AP variant associated with incidence of type 2 diabetes in calcium channel blocker users in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  A Y Chu; J Coresh; D E Arking; J S Pankow; G F Tomaselli; A Chakravarti; W S Post; P H Spooner; E Boerwinkle; W H L Kao
Journal:  Diabetologia       Date:  2009-11-27       Impact factor: 10.122

5.  The Rotterdam Study: 2012 objectives and design update.

Authors:  Albert Hofman; Cornelia M van Duijn; Oscar H Franco; M Arfan Ikram; Harry L A Janssen; Caroline C W Klaver; Ernst J Kuipers; Tamar E C Nijsten; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2011-08-30       Impact factor: 8.082

Review 6.  Mechanisms of NOS1AP action on NMDA receptor-nNOS signaling.

Authors:  Michael J Courtney; Li-Li Li; Yvonne Y Lai
Journal:  Front Cell Neurosci       Date:  2014-08-27       Impact factor: 5.505

7.  PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus.

Authors:  Tao Wang; Jin-Fang Song; Xue-Yan Zhou; Cheng-Lin Li; Xiao-Xing Yin; Qian Lu
Journal:  BMC Med Genomics       Date:  2021-11-12       Impact factor: 3.063

8.  The Rotterdam Study: 2010 objectives and design update.

Authors:  Albert Hofman; Monique M B Breteler; Cornelia M van Duijn; Harry L A Janssen; Gabriel P Krestin; Ernst J Kuipers; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Johannes R Vingerling; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2009       Impact factor: 8.082

9.  Serum Proteome Changes in Healthy Subjects with Different Genotypes of NOS1AP in the Chinese Population.

Authors:  Feng Jiang; Congrong Wang; Rongxia Li; Quanhu Sheng; Cheng Hu; Rong Zhang; Qichen Fang; Yuqian Bao; Kunsan Xiang; Rong Zeng; Weiping Jia
Journal:  J Diabetes Res       Date:  2013-04-07       Impact factor: 4.011
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.